Coronavirus vaccines are known to be less protective in people with the blood cancer multiple myeloma, such as former U.S. Secretary of State Colin Powell, who died on Oct. 18 of complications from Covid-19 despite being fully vaccinated. Additionally, in a paper in the journal Stem Cell Reports, researchers said numerous businesses have made unsubstantiated and inaccurate claims about supposed stem cell products to treat Covid-19.

AstraZeneca requested emergency use authorization from U.S. regulators for the company’s new treatment to prevent Covid-19 for people who respond poorly to vaccines because of a weakened immune system.

A protein called CD47 that helps damaged cells avoid destruction by the immune system may be contributing to severe cases of Covid-19, researchers suggested in a report. In other news, Gilead Sciences Inc.’s intravenous antiviral drug remdesivir helped keep high-risk Covid-19 patients out of the hospital in a randomized trial.

Severe Covid-19 may trick the immune system into producing so-called autoantibodies that have the potential to eventually attack healthy tissue and cause inflammatory diseases, researchers warned in a paper published in Nature Communications. Another study suggests that the virus that causes Covid-19 may be getting better at traveling into the air

The U.S. Food and Drug Administration said on Sept. 16 it has revised the FDA’s emergency use authorization for Eli Lilly’s Covid-19 antibody cocktail to include for use in patients who have been exposed to the virus and are at high risk for progression to severe disease.

Moderna Inc. on Sept. 1 asked the U.S. Food and Drug Administration to allow the use of a third booster dose of the company’s Covid-19 vaccine.

A new study on Covid-19 behavior has found that patients affected by the virus might have died due to a buildup of coronavirus directly in the lungs and not because of a secondary infection. 

The National Institutes of Health (NIH) is testing a booster shot of Covid-19 vaccines in people with autoimmune diseases who have not responded well to the primary vaccine course.

Llama antibodies could soon be playing a role in the global fight against Covid-19, if clinical trials being conducted by a Belgian biomedical start-up live up to their early promise.

Trial data from AstraZeneca on Aug. 20 raised the prospect of a new treatment to prevent Covid-19 beyond vaccines, giving hope in particular for people who respond poorly to immunization shots.